The narrow eligible patient others miss, found inside the largest populations.

Modern obesity and GLP-1 trials rarely enroll on BMI alone. They gate on comorbidity, on prior-therapy washout, and demand large, diverse, multinational enrollment fast. Leapcure brings exactly that recruiting profile, solved in pieces on adjacent programs: finding a narrow eligible slice inside a huge population, confirming treatment history before referral, and reaching the cardiometabolic-comorbid patient.

Talk to our metabolic teamSee how it works →
50+
Countries reached, multilingual
cross-portfolio recruitment capability
40+
Advocacy partnerships
cross-portfolio; obesity partners to be added once confirmed
~8,900
Pre-screened inside a very large population
completed Phase 2 pulmonary program, narrow-slice model

Understanding Obesity as a Clinical Trial Indication

Obesity is a chronic, relapsing cardiometabolic disease, not a lifestyle state, and it drives or worsens Type 2 diabetes, cardiovascular disease, MASH, and obstructive sleep apnea. According to the CDC and NHANES, roughly 40 percent of US adults have obesity. (This epidemiology is third-party context and is being confirmed and dated with Medical before production go-live.) On its surface obesity looks like the easiest indication in the world to enroll.

For sponsors, that scale is a trap. Modern obesity and GLP-1 trials rarely enroll on BMI alone. They gate on comorbidity, Type 2 diabetes, MASH, cardiovascular disease, or obstructive sleep apnea, they require prior or washout of anti-obesity medications, a treatment-naive-style requirement in the middle of a GLP-1 boom, and they demand large, diverse, multinational enrollment fast. Generic volume campaigns flood sites with people who fail these criteria, and the patients a protocol actually needs, the narrow eligible slice inside a very large population, stay hard to find.

That recruiting profile is one Leapcure has solved in pieces on adjacent, completed programs. Finding the narrow eligible slice inside a very large population: on a completed Phase 2 pulmonary program in severe respiratory disease we pre-screened roughly 8,900 patients and enrolled the narrow eligible segment across 7 countries. Recruiting treatment-naive and washout populations with history confirmed before referral: across two completed Phase 2 IPF studies we recruited antifibrotic-naive patients and ran screen-fail below the study average, the same rigor a GLP-1 washout requirement demands. Reaching the cardiometabolic-comorbid population: on a completed Phase 2 diabetic kidney disease trial we referred 5,469 patients against strict biomarkers, and on an active resistant hypertension study we have reached 7,500+ interested patients (in-progress reach, not enrollment).

The Challenge

Obesity trials no longer enroll on BMI alone. The work is finding a narrow, comorbidity-defined, prior-therapy-gated slice inside the largest patient population in medicine, fast and diversely.

A huge population, but a narrow eligible core

Roughly 40 percent of US adults have obesity, yet each protocol needs a specific slice. Generic volume campaigns flood sites with interested people who fail comorbidity or eligibility criteria, burying coordinators while the protocol's real target stays unfound.

On a completed Phase 2 pulmonary program Leapcure found the narrow eligible segment inside a very large population, pre-screening roughly 8,900 patients and enrolling across 7 countries. The 'huge population, narrow eligible core' problem is the same shape.

Comorbidity gating, not BMI alone

Modern obesity trials enrich for Type 2 diabetes, cardiovascular disease, MASH, or obstructive sleep apnea. Reaching the comorbidity-defined patient is a different task from reaching anyone with a high BMI, and most volume vendors cannot do it.

Leapcure recruited the cardiometabolic-comorbid population on a completed diabetic kidney disease Phase 2 (5,469 referred against strict biomarkers) and on an active resistant hypertension study (7,500+ interested, in-progress reach, not enrollment).

Prior-therapy and GLP-1 washout requirements

In the middle of a GLP-1 boom, many protocols require washout or specific prior-therapy history, a treatment-naive-style requirement. Confirming that history before referral is its own recruiting task, and one volume campaigns skip.

Across two completed Phase 2 IPF studies Leapcure recruited a treatment-naive population and confirmed prior-therapy history before referral, running screen-fail below the study average, the same rigor a GLP-1 washout requirement demands.

Speed, diversity, and multinational scale

Obesity programs demand large, diverse, often global enrollment quickly. Recruitment that cannot operate multilingually and representatively across geographies leaves enrollment slow and unrepresentative.

Across its portfolio Leapcure has reached 50+ countries multilingually with 40+ advocacy partnerships and a representative-recruitment model.

Three steps. One strategy built for your obesity trial.

Leapcure solves the recruiting problem, comorbidity plus prior-therapy gating plus speed and diversity, applying capability proven on adjacent programs.

1

Find the narrow eligible slice inside the largest population

We reach the comorbidity-defined patient, Type 2 diabetes, cardiovascular disease, MASH, or obstructive sleep apnea, through advocacy-led outreach, precision digital, and multilingual campaigns, mapped to your eligibility criteria and site geographies. This is the narrow-slice-inside-a-huge-population capability proven on a completed pulmonary program.

2

Confirm comorbidity and prior-therapy history before referral

Every referral is pre-screened before a site sees the patient. We confirm comorbidity enrichment criteria and prior-therapy or GLP-1 washout history, the same rigor Leapcure applied to treatment-naive recruitment on completed programs. Sites receive verified-eligible, documentation-ready patients, not raw BMI volume.

3

Deliver fast, diverse, multinational enrollment

We run multilingual, representative campaigns and track referral quality across geographies, rebalancing to keep enrollment fast and diverse. This is cross-portfolio capability across 50+ countries, applied to your obesity protocol.

Four channels. Capability-led. Built for obesity trials.

Leapcure finds the narrow eligible slice, confirms comorbidity and prior-therapy history before referral, delivers diverse multinational reach, and makes your trial retrievable to the AI engines patients now use.

Narrow-Slice Reach Inside Large Populations

  • •We find the comorbidity-defined eligible slice inside very large populations, proven on a completed pulmonary program that pre-screened roughly 8,900 patients and enrolled the narrow segment across 7 countries.
  • •Reach spans advocacy-led outreach and precision digital across 40+ cross-portfolio partnerships.
  • •Obesity-specific patient organizations are being confirmed by Marketing and are not named until brand-approved, so advocacy appears here only as a cross-portfolio count.

Comorbidity and Prior-Therapy Pre-Screening

  • •Every referral is pre-screened before a site sees the patient, confirming comorbidity enrichment (Type 2 diabetes, cardiovascular disease, MASH, OSA) and prior-therapy or GLP-1 washout history.
  • •This is the same rigor Leapcure applied to treatment-naive recruitment on completed programs, where prior-therapy history was confirmed before referral.
  • •Sites receive verified-eligible, documentation-ready patients, not raw BMI volume.

Fast, Diverse, Multinational Enrollment

  • •Multilingual, representative campaigns across 50+ countries support the speed and diversity obesity programs demand.
  • •We track referral quality across geographies and rebalance to keep enrollment fast and representative.
  • •This is cross-portfolio recruitment capability, applied to your obesity protocol.

Answer-Engine and AI-Search Visibility

  • •Obesity patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. We make your trial's information genuinely retrievable for those engines.
  • •We do this with crawlable, factually rich content, cited sources, and presence in the advocacy and ClinicalTrials.gov sources AI engines actually cite, not schema tricks or content written for machines.
  • •This puts your obesity study where high-intent patients are already searching.

Living with obesity? A clinical trial may be an option.

If you are living with obesity, a clinical trial may offer access to investigational treatments alongside your regular care, never instead of it. We know obesity is a medical condition, often managed alongside diabetes, heart, or liver health, and that eligibility can involve your health history and current medications. Leapcure's team explains what a trial involves, answers your questions honestly and without judgment, and supports you at your pace.

See if an obesity trial may be right for you
Leapcure kangaroo mascot

Leapcure brings the exact recruiting profile modern obesity and GLP-1 trials require, proven in pieces on adjacent completed programs: finding the narrow eligible slice inside a huge population, confirming prior-therapy history before referral, and reaching the cardiometabolic-comorbid patient, all delivered fast, diversely, and multilingually across 50+ countries. Talk to our metabolic team about your active or upcoming obesity study.

Talk to our metabolic team